Merck (MRK) Accounts Payables (2009 - 2026)
Merck (MRK) reported Accounts Payables of $3.9 billion for Q1 2026, up 2.09% year-over-year from $3.8 billion in Q1 2025, and down 12.28% quarter-over-quarter from $4.4 billion in Q4 2025.
Merck (MRK) Accounts Payables (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Accounts Payables data on file, last reported at $3.9 billion in Q1 2026.
- Accounts Payables for Q1 2026 came in at $3.9 billion, up 2.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 billion (up 2.09% YoY), and the FY2025 annual result was $4.4 billion, up 7.97% from the prior year.
- Accounts Payables slipped to $3.9 billion in Q1 2026 per MRK's latest filing, from $4.4 billion in the prior quarter.
- Over five years, Accounts Payables peaked at $4.4 billion in Q4 2025 and troughed at $3.4 billion in Q3 2022.
- A 5-year average of $3.8 billion and a median of $3.7 billion in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables slipped 10.65% in 2022, then climbed 15.64% in 2025.
- A 5-year view of Accounts Payables shows it stood at $4.3 billion in 2022, then declined by 8.02% to $3.9 billion in 2023, then gained by 4.0% to $4.1 billion in 2024, then climbed by 7.97% to $4.4 billion in 2025, then fell by 12.28% to $3.9 billion in 2026.
- Business Quant data shows MRK's Accounts Payables at $3.9 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -19.33 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 10.46 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.86 Bn |
| Dec 31, 2025 | 4.40 Bn |
| Sep 30, 2025 | 4.15 Bn |
| Jun 30, 2025 | 3.89 Bn |
| Mar 31, 2025 | 3.78 Bn |
| Dec 31, 2024 | 4.08 Bn |
| Sep 30, 2024 | 3.59 Bn |
| Jun 30, 2024 | 3.52 Bn |
| Mar 31, 2024 | 3.51 Bn |
| Dec 31, 2023 | 3.92 Bn |
| Sep 30, 2023 | 3.51 Bn |
| Jun 30, 2023 | 3.44 Bn |
| Mar 31, 2023 | 3.68 Bn |
| Dec 31, 2022 | 4.26 Bn |
| Sep 30, 2022 | 3.37 Bn |
| Jun 30, 2022 | 3.48 Bn |
| Mar 31, 2022 | 3.72 Bn |
| Dec 31, 2021 | 4.61 Bn |
| Sep 30, 2021 | 3.37 Bn |
| Jun 30, 2021 | 3.90 Bn |